VascVersa Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$600K
- Investors
-
9
VascVersa General Information
Description
Developer of regenerative medicine designed to deliver new cell therapies that promote vascular regeneration and repair. The company's technology provides a unique cell therapy for blood vessel regeneration by stimulating new blood vessel formation, leading to an improved blood supply and long-term healing, enabling healthcare professionals to treat patients suffering from ischaemic diseases.
Contact Information
Website
www.vascversa.comCorporate Office
- 63 University Road
- Belfast BT7 1NF
- Northern Ireland, United Kingdom
Corporate Office
- 63 University Road
- Belfast BT7 1NF
- Northern Ireland, United Kingdom
VascVersa Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Seed Round | 09-Aug-2022 | $600K | Completed | Generating Revenue | ||
| 5. Grant | 01-Feb-2022 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 01-Apr-2021 | Completed | Generating Revenue | |||
| 3. Grant | 01-Feb-2020 | Completed | Startup | |||
| 2. Accelerator/Incubator | 01-Jan-2020 | $261K | $261K | Completed | Startup | |
| 1. University Spin-Out | 20-Dec-2018 | Completed | Startup |
VascVersa Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
VascVersa Patents
VascVersa Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202501461-D0 | Cells for treatment of ischemic disease | Pending | 31-Jan-2025 | ||
| WO-2026162769-A1 | Cells for treatment of ischemic disease | Pending | 31-Jan-2025 | ||
| AU-2024317407-A1 | Cell culture methods and composition | Pending | 28-Jul-2023 | ||
| EP-4753723-A1 | Cell culture methods and composition | Pending | 28-Jul-2023 | ||
| WO-2025026877-A1 | Cell culture methods and composition | Inactive | 28-Jul-2023 | C12N5/069 |
VascVersa Signals
VascVersa Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| College Green Ventures | Venture Capital | Minority | ||
| Innovation Investment Fund | Venture Capital | Minority | ||
| Invest Northern Ireland | Limited Partner | Minority | ||
| Clarendon Fund Managers | Venture Capital | Minority | ||
| Halo Business Angel Network | Angel Group | Minority |
VascVersa FAQs
-
When was VascVersa founded?
VascVersa was founded in 2018.
-
Where is VascVersa headquartered?
VascVersa is headquartered in Belfast, United Kingdom.
-
What is the size of VascVersa?
VascVersa has 6 total employees.
-
What industry is VascVersa in?
VascVersa’s primary industry is Drug Discovery.
-
Is VascVersa a private or public company?
VascVersa is a Private company.
-
What is the current valuation of VascVersa?
The current valuation of VascVersa is .
-
What is VascVersa’s current revenue?
The current revenue for VascVersa is .
-
How much funding has VascVersa raised over time?
VascVersa has raised $1.21M.
-
Who are VascVersa’s investors?
College Green Ventures, Innovation Investment Fund, Invest Northern Ireland, Clarendon Fund Managers, and Halo Business Angel Network are 5 of 9 investors who have invested in VascVersa.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process